| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 108.2 | 116.1 |
| Profit before tax | -48.0 | -36.0 |
| Net income | -46.1 | -36.0 |
| EPS (diluted, $ a share) | $-0.04 | $-0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -6.8% |
|---|---|
| Operating margin | -58.2% |
10-Q filed with the SEC, NASDAQ: ZLAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zai Lab Ltd: key numbers
- Share price
- $23.47Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zai Lab Ltd
All →Zai Lab Director Richard Gaynor Buys $33.4K of Stock
Richard Gaynor, Director, bought 1,228 shares of Zai Lab Ltd at $27.19 a share, worth $33.4K in total on Nov 10, 2026. Shares held after the trade: 81,965 (+1.5%).
- Value
- $33.4K
- Shares
- 1,228
- Price
- $27.19
- Role
- Director
- Holding change
- +1.5%
- Trade date
- Nov 10, 2026
Zai Lab Earnings Call: Key Takeaways
Zai Lab is pivoting toward a global oncology player with Zozi's 81.8% ORR in small cell lung cancer and a $250 million capital raise.
- Call
- Nov 5, 2026, 8:00 AM ET
Zai Lab Financial Results
Zai Lab reported third quarter 2026 total revenues of $108.2 million, representing a 2% sequential increase in net product revenue. The company highlighted positive clinical data for its internally developed ADC, zocilurtatug pelitecan (zoci), in small cell lung cancer and expects 2027 to be a pivotal year with its first potential U.S. BLA submission.
- Term
- Q3 2026
“We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally. The strong first-line combination data for zocilurtatug pelitecan (zoci) presented at ESMO strengthen our confidence in its potential to become an ADC backbone of choice in small cell lung cancer.”
Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab
“This profile supports taking a standard chemotherapy-free regimen into a global Phase 3 study and gives us a strong foundation to build on with T-cell engager combinations. Our registrational programs in SCLC and neuroendocrine carcinomas are advancing toward readouts that could support our first U.S. BLA submission in 2027.”
Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab
Zai Lab Capital Raise of $250M
Zai Lab Limited entered into a securities purchase agreement with accredited investors for a private placement (PIPE) of 11,340,000 American depositary shares (ADSs). The company expects to receive gross proceeds of approximately $250 million to fund pipeline development and general corporate purposes. The ADSs are priced at $22.04 each, and the company has agreed to file a registration statement for the resale of these securities.
- Value
- $250M